Marijuana, CBD and the CDL

No. A driver covered by the DOT drug and alcohol rules may not use marijuana, and a state law making it legal, recreational or medical, does not change that. 49 CFR 382.213 and 392.4 bar duty after Schedule I use, the DOT test still looks for marijuana under 40.82, and a medical examiner cannot certify a driver who uses a Schedule I drug. In April 2026 marijuana in FDA-approved products and marijuana under a state medical license moved to Schedule III, but all other marijuana is still Schedule I, and the DOT testing rule has not been amended.

This page states what the rules say as of 27 September 2026. It is not legal advice. The status of marijuana under federal law is moving, and the section on rescheduling below says exactly what has and has not happened.

The rules that apply to a CDL driver

Part 382 covers drivers who must hold a CDL under Part 383 (382.103(a)). Drivers of smaller commercial vehicles that do not need a CDL are outside Part 382's testing programme but still under 392.4 and, for the medical card, 391.41(b)(12).

"It is legal in my state"

State legalization does not reach these rules. They are federal regulations that apply to CDL drivers and their employers in every state, and each one is written around the federal schedules in 21 CFR Part 1308, not state law. Section 40.151(e) was written specifically for state medical marijuana laws and tells the MRO to disregard a recommendation made under one.

Off duty, days before

People often ask whether use on a day off is allowed if the driver is not impaired at work. Section 382.213(a) is written around reporting for duty "when the driver uses" a Schedule I substance, and it contains no hours-based window like the four-hour alcohol rule in 382.207. In practice the question is settled by the test: a verified positive for marijuana metabolites is a violation under 382.215 regardless of when the use happened. The urine cutoffs are 50 ng/mL of the THC metabolite THCA on the initial test and 15 ng/mL on confirmation (40.85(a)).

What changed in April 2026, and what did not

On 28 April 2026 the Justice Department published a final order, effective that day, placing two kinds of marijuana in Schedule III (91 FR 22714). The eCFR now lists them in 21 CFR 1308.13(g)(2) to (4):

• marijuana, marijuana extract and naturally derived delta-9-THC in an FDA-approved drug product; and
• the same substances subject to a state medical marijuana license, meaning a state license to manufacture, distribute or dispense marijuana for medical purposes.

The same order says any other form of marijuana remains a Schedule I controlled substance, and that synthetically derived THC remains in Schedule I. Separately, DEA reopened hearings on the 2024 proposal to move marijuana as a whole to Schedule III: a notice published the same day (91 FR 22777) scheduled a hearing to start on 29 June 2026. As of 27 September 2026, no final rule rescheduling marijuana generally had been published in the Federal Register.

What this means for a CDL driver, rule by rule:

• Recreational marijuana is still Schedule I. 382.213(a), 392.4(a)(1) and 391.41(b)(12)(i) apply exactly as before.
• The DOT test is unchanged. 40.82(a) still requires marijuana metabolites to be tested, and the eCFR text of Part 40 dated 23 September 2026 contains no amendment responding to the April order.
• State medical marijuana is where the rule text has not caught up. Section 40.151(e) still speaks of physician recommendations of a Schedule I drug under "medical marijuana" laws, while marijuana under a state medical license is now Schedule III. The provisions that would govern a Schedule III drug, 382.213(b), 391.41(b)(12)(ii) and 40.137(a), turn on a prescription from a licensed practitioner familiar with the driver's history who has advised the drug will not affect safe driving, and on a legally valid prescription consistent with the Controlled Substances Act. DOT had not, as far as the Federal Register shows, published any change to Part 40 on this point, and we could not reach DOT's drug and alcohol policy office website from here to check for guidance. Until DOT says otherwise in writing, do not assume a state medical card protects a CDL.

If marijuana is rescheduled generally in future, the same questions will arise for everyone: DOT would still test for it unless it amends 40.82, and any use would still have to fit the prescription language in 382.213(b) and 391.41(b)(12)(ii). Watch for a DOT Federal Register notice, not news coverage.

CBD

CBD is the part of this that catches careful drivers. Three points from the rules:

• The MRO cannot accept it as an explanation. Under 40.151(f), use of hemp or other non-prescription marijuana-related products is not a legitimate medical explanation for a marijuana positive.
• The test does not look for CBD. It looks for a THC metabolite. A CBD product that contains THC can therefore produce a positive, and the label is the manufacturer's claim, not a guarantee.
• The legal definition of hemp is changing. The April 2026 order notes that hemp is currently defined by delta-9-THC concentration of not more than 0.3 percent on a dry weight basis, and that from 12 November 2026 the definition refers to total tetrahydrocannabinols, including THCA, of not more than 0.3 percent (Public Law 119-37, section 781). Products that were hemp under the old test may not be under the new one.

FDA-approved drug products containing CBD with no more than 0.1 percent THC have been in Schedule V since 2018 (83 FR 48950, as described in the April 2026 order). A prescription for one of those is a different situation from a shop-bought oil and would go through the prescription route described on the medications page.

At the DOT physical

Marijuana also comes up at the medical exam, separately from testing. Section 1 of the medical examination report, Form MCSA-5875, asks whether you have used an illegal substance within the past two years and whether you have ever failed a drug test or been dependent on an illegal substance. You sign a statement that your answers are accurate and complete.

The examiner then applies 391.41(b)(12). Paragraph J.1 of the Medical Advisory Criteria in Appendix A to Part 391, updated in January 2024, puts the reasoning plainly: federal law prohibits Schedule I drugs from being prescribed for any purpose, so a medical examiner cannot physically qualify an individual who uses them. Paragraph J.4 lets the examiner request a non-DOT drug test to help decide, including when there are signs a driver has not disclosed use of a scheduled drug. That test is the examiner's tool and is not a DOT test (40.13(e)).

Those criteria were written before the April 2026 order. How an examiner should treat marijuana obtained under a state medical license, now in Schedule III, is not addressed in the criteria or the rule text we could read. The examiner decides, and under 391.41(b)(12)(ii) the question for any non-Schedule I drug is whether it was prescribed by a licensed medical practitioner who knows your history and has advised that it will not affect safe driving.

Delta-8 and other hemp-derived THC products

Gas-station THC products are sold as hemp. Two statements in the April 2026 order are relevant. First, the order does not affect hemp, because hemp is excluded from the federal definition of marijuana. Second, THC that can only be made by artificial synthesis is outside the definition of marijuana, and the order says synthetic THC remains in Schedule I; it gives delta-10-THC as an example. Whatever the legal status of a given product, the DOT test looks for a THC metabolite, and 40.151(f) stops the MRO from accepting use of a hemp or other non-prescription marijuana-related product as an explanation. The rules offer no safe version of these products for a tested driver.

Owner-operators

Being your own boss does not take you out of Part 382. 382.107 defines "driver" to include independent owner-operator contractors, and 382.103(b) requires an employer who employs himself or herself as a driver to comply with both the employer and the driver requirements, including a random testing programme with at least two covered employees in the selection pool. An owner-operator who uses marijuana has the same exposure as a company driver.

What a positive costs

• Immediate removal from safety-sensitive duty (40.23(a)).
• No return until the return-to-duty process in Part 40, Subpart O is complete (40.23(d)).
• A Clearinghouse record, and a state downgrade of the CLP or CDL within 60 days of the state being told you are prohibited (383.73(q)).
• At the next physical, the history questions ask whether you have used an illegal substance within two years and whether you have ever failed a drug test. A false answer runs into 390.35.

Refusing the test is not a way out: 382.211 bars refusals, and 40.191 defines them broadly, including adulterating or substituting a specimen.

Example: two drivers in a legal state

Illustration only. Driver C lives in a state with legal adult-use marijuana and uses it on a Saturday. On Tuesday he is selected for a random test and the confirmation shows THCA above 15 ng/mL. The MRO interviews him; state legality is not a legitimate medical explanation, so the result is verified positive. Driver D uses a CBD tincture bought online, labelled "THC-free", every evening. Her random test confirms THCA above the cutoff. Under 40.151(f) the MRO cannot accept CBD use as an explanation, and the result is verified positive. Both are removed from duty and both must complete the return-to-duty process.

Common misreadings

• "Rescheduling made weed legal for truckers." Only FDA-approved products and marijuana under a state medical license moved, and the DOT rules still test for it.
• "I have a medical card." 40.151(e) was written to exclude exactly that argument, and the rule text has not been changed.
• "CBD is legal, so it cannot fail me." Legality of the product and the result of the test are separate questions.
• "It was days ago." The test measures metabolite, not impairment.